Genetics-Based Risk Model to Stratify Survival Outcomes of Patients With AML Treated With Venetoclax- Azacitidine
An analysis of treatment-naïve patients with acute myeloid leukemia (AML) receiving venetoclax plus azacitidine demonstrates that the European LeukemiaNet (ELN) AML genetic risk classification systems ...
Will Menin Inhibitors Revolutionize the Treatment of AML?
Few targeted therapies are available for the treatment of acute myeloid leukemia (AML). Menin inhibitors constitute a new class of agents that target the underlying biology of NPM1-mutant and KMT2A-rearranged acute ...
Pediatric T-LBL But Not T-ALL Harbors TRB::NOTCH1 Fusions With Increased Relapse Risk
NOTCH1 gene fusions in the T-cell receptor ß (TRB) were identified in some children with T-cell lymphoblastic lymphoma (T-LBL) and were associated with increased relapse risk ...
Study Examines Development of Paraparesis, Quadriparesis in Pediatric Patients With B-ALL Treated With CAR T-Cell Therapy
As more pediatric patients are being treated with chimeric antigen receptor (CAR) T-cell therapy, researchers at the Children’s Hospital of Philadelphia (CHOP) have described new, very rare toxicities of paraparesis and ...
Dose-Adjusted VEN-HMA Regimens Safe, Effective in Very Old Patients With AML
A significant portion of patients in their 80s and 90s with acute myeloid leukemia (AML) can live longer if they are treated with dose-modified venetoclax (VEN) plus a hypomethylating agent ...
Straight-to-Transplantation Approach Comparable to Remission Induction in Difficult Acute Myeloid Leukemia Cases
In the first randomized trial to assess whether complete remission (CR) induction or direct-to- transplantation is best for relapsed or poorly responsive acute myeloid leukemia (AML) ...
ATRA-ATO Regimen Demonstrates Superior EFS in Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia
Previous studies show low- to intermediate-risk acute promyelocytic leukemia (APL) responds favorably to frontline all-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) over the standard ...
Which Inhibitor Should Be Used to Treat FLT3-Positive AML?
The use and array of FLT3 inhibitors continues to mature and proliferate as 2023 brought another landmark phase III clinical trial of an upfront FLT3 inhibitor and another in the ...
Gilteritinib Effective for Post-Transplant Maintenance for Acute Myeloid Leukemia
While standard polymerase chain reaction (PCR) can detect the internal tandem duplication mutation of FLT3 (FLT3-ITD) that is common in patients with acute myeloid leukemia (AML), the mutations detected this way ...
Adults With Acute Myeloid Leukemia Follow One of Four Trajectories of Physical Well-Being
New results indicate that while many adults with acute myeloid leukemia (AML) experience some decline in physical health, patients can be grouped into four distinct trajectories of physical well-being ...
